In the wake of the patent rejection, companies such as Natco Pharma may begin work on their own, less expensive versions of the HCV drug. Larger pharmaceutical companies, such as Pfizer and Novartis AG, have had patents rejected in India as well, due to stricter standards, according to the report.
Gilead Sciences has the option to appeal the patent rejection.
More articles on gastroenterology:
Are gastroenterologists looking for new avenues to increase practice revenue? 10 statistics
5 gastroenterologists leading GI mega-practices
7 New Year’s Resolutions from the AGA
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.